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Abstract 
Bitter orange (Citrus aurantium) extract is widely used in dietary supplements for weight 
management and sports performance. Its primary protoalkaloid is p-synephrine. Most studies 
involving bitter orange extract and p-synephrine have used products with multiple ingredients. 
The current study assessed the thermogenic effects of p-synephrine alone and in conjunction 
with  the  flavonoids  naringin  and  hesperidin  in  a  double-blinded,  randomized,  place-
bo-controlled protocol with 10 subjects per treatment group. Resting metabolic rates (RMR), 
blood pressure, heart rates and a self-reported rating scale were determined at baseline and 
75 min after oral ingestion of the test products in V-8 juice. A decrease of 30 kcal occurred in 
the placebo control relative to baseline. The group receiving p-synephrine (50 mg) alone 
exhibited a 65 kcal increase in RMR as compared to the placebo group. The consumption of 
600 mg naringin with 50 mg p-synephrine resulted in a 129 kcal increase in RMR relative to the 
placebo group. In the group receiving 100 mg hesperidin in addition to the 50 mg p-synephrine 
plus 600 mg naringin, the RMR increased by 183 kcal, an increase that was statistically sig-
nificant with respect to the placebo control (p<0.02). However, consuming 1000 mg hes-
peridin with 50 mg p-synephrine plus 600 mg naringin resulted in a RMR that was only 79 kcal 
greater than the placebo group. None of the treatment groups exhibited changes in heart rate 
or  blood  pressure  relative  to  the  control  group,  nor  there  were  no  differences  in 
self-reported ratings of 10 symptoms between the treatment groups and the control group. 
This unusual finding of a thermogenic combination of ingredients that elevated metabolic rates 
without corresponding elevations in blood pressure and heart-rates warrants longer term 
studies to assess its value as a weight control agent. 
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Introduction 
The bioflavonoids hesperetin and naringenin are 
widely distributed in citrus fruits and juices as their 
glycosides,  hesperidin  and  naringin,  respectively. 
They are present in Citrus aurantium as well as a wide 
variety of other Citrus species [1]. The sugar moieties 
for both flavonoids consist of rhamnose plus glucose, 
which must be removed in the intestinal tract before 




of these flavonoids in human subjects has been exten-
sively studied and depends in part upon the forms in 
which they are ingested (juice or fruit, glycoside or 
aglycone, capsule, tablet, etc.) [4-8].  
Experiments involving human subjects, animals 
and  cell  culture  systems  have  shown  that  the  two 
flavonoids exhibit a wide range of potentially benefi-
cial physiological and biochemical effects. Naringen 
and/or  hesperidin  or  their  aglycones  have  been 
shown to improve insulin sensitivity and glucose tol-
erance [9], prevent accumulation of triglycerides [9], 
inhibit cholesterol biosynthesis [10, 11], and serve as 
antioxidants and anti-inflammatory agents [12, 13] as 
well as hepatoprotectants [14] and neuroprotectants 
[15]. However, the effects of naringin and hesperidin 
on metabolic rate and energy utilization have not been 
previously assessed. 
Studies  have  suggested  that  p-synephrine  has 
thermogenic and lipolytic activities [16-18], increasing 
energy metabolism [19, 20] as well as athletic perfor-
mance [21]. p-Synephrine is the primary protoalkaloid 
in  bitter  orange  extract  which  is  derived  from  the 
immature  fruits  of  Citrus  aurantium  [22-25],  and  is 
widely distributed in other Citrus species [22, 23, 26]. 
The safety of p-synephrine and bitter orange extract 
has  recently  been  reviewed  [27],  and  based  on  the 
available studies in animals, humans and cell culture 
systems, it has been concluded that when taken orally 
and in recommended amounts both are safe.  
p-Synephrine is widely used in combination with 
caffeine and other ingredients in products designed to 
support  weight  management  [19,  28].  However,  no 
studies  have  been  reported  comparing  the  thermo-
genic effects of p-synephrine when combined with the 
flavonoids hesperidin and naringin. This pilot study 
was designed to examine these effects using a com-
parative  effectiveness  research  (CER)  study  design 
[29]  in  a  double-blinded,  randomized,  place-
bo-controlled  protocol  to  compare  the  effects  of 
p-synephrine alone and in combination with different 
amounts  of  hesperidin  and  naringin  on:  (1)  resting 
metabolism, (2) blood pressure, (3) resting heart-rate, 
and (4) self-reported mood/energy levels in healthy 
human subjects.  
Material and methods:  
A total of 50 participants gave written informed 
consent in compliance with the Helsinki Declaration 
and  approved  by  Integrative  Health  Technologies’ 
Ethics Committee. Participants fasted for 8-10 hours 
without  consuming  caffeinated  beverages,  nicotine, 
exercising or participating in vigorous physical activ-
ities. Upon reporting to the research center, partici-
pants completed the 10-item self report in Table 1.  
After  remaining  seated  in  an  isolated  area  for 
10-15 min., participants completed measurements of 
their  blood  pressure,  resting  heart-rate  and  resting 
metabolism  using  Micro  Life’s  MedGem®  Indirect 
Calorimeter  (Microlife  Medical  Home  Solutions, 
Golden,  CO.  80401).  The  MedGem®  is  a  hand-held, 
self-calibrating  calorimeter  that  measures  oxygen 
consumption  (VO2)  to  determine  resting  metabolic 
rate (RMR). In conjunction with the study, test-retest 
reliabilities  of  the  instrument  were  measured  on  41 
subjects  from  test-retest  periods  ranging  from  1-17 
days between tests. The average reliability coefficient 
was 90.2 %, a coefficient that was consistent over the 
four test-retest periods.  
p-Synephrine  was  administered  in  the  form  of 
the patented bitter orange extract Advantra Z® which 
contained 60 % of this active material. Naringin and 
hesperidin  were  96  %  pure.  All  test  materials  were 
obtained  from  Nutratech  Inc.  (West  Caldwell,  NJ).
 









Subsequent to RMR measurements, participants 
were  randomly  assigned  to  one  of  the  five  dou-
ble-blinded treatment conditions in which they con-
sumed one ounce of V-8 juice containing the following 
ingredient variations: 
Group 1: Placebo (V-8 juice only) 
Group 2: Advantra Z® (50 mg of p-synephrine)  
Group 3: Advantra Z® with 0 mg hesperidin and 
600 mg naringin 
Group 4: Advantra Z® with 100 mg hesperidin 
and 600 mg naringin 
Group 5: Advantra Z® with 1,000 mg hesperidin 
and 600 mg naringin 
After remaining seated and resting for 45 min., 
participants  completed  a  second  self  report  rating 
scale. After 75 min., a third and final self report rating 
scale  was  completed,  and  measurements  of  blood 
pressure, heart-rate and RMR were determined.  
Statistical Analyses 
ANOVAs were calculated between the groups’ 
baseline, ending and change scores for each treatment 
group in addition to Dunnett’s t-test between each of 
the treatment groups and the placebo group.  
Results 
Figure 1 shows the changes in resting metabolic 
rates (RMRs) from baseline expressed as kcals for each 
of  the  treatment  groups  (N=10  per  group).  As  ex-
pected, a small decrease occurred in the RMR of the 
placebo group since these participants continued their 
8-10  hour  fast  (Group1).  Increases  occurred  in  the 
RMR of all treatment groups. As compared to place-
bo, 50 mg p-synephrine (Advantra Z®) alone (Group 
2) more than doubled consumption by 65 kcals over 
placebo. In Group 3, adding 600 mg naringin to the 50 
mg p-synephrine further increased calorie consump-
tion more than three-fold to 122 kcals over placebo. 
The addition of 100 mg hesperidin to the p-synephrine 
plus naringin in Group 4 resulted in a further increase 
in calorie consumption by 5-fold to 183 kcal over pla-
cebo. However, in Group 5, when the amount of hes-
peridin  consumed  in  conjunction  with  the  50  mg 
p-synephrine plus 600 mg naringin was increased to 
1000  mg,  the  increase  in  calorie  consumption  over 
placebo was only 79 kcal, an increase between calorie 
consumption in the absence of hesperidin and in the 






Figure 1. Over-Placebo Comparisons of Changes in Resting Metabolic Rates 75 Minutes from Baseline (Expressed in kcal) 
With a Supplement Containing the Variations in Advantra Z, Naringin, and Hesperidin 
 





In spite of the low levels of statistical power in 
these groups of only 10 subjects, the increases in RMR 
in  Group  4  was  significantly  greater  than  placebo 
(P=0.039) and Advantra Z alone (Group 2). It is also 
worth noting the a repeated-measures Students’ t-test 
revealed that the changes from baseline in Group 3 
and  Group  4  were  both  statistically  significant 
(P=0.001 and 0.030, respectively).  
Table 2 shows changes in blood pressures and 
resting heart-rates from baseline to the ending test for 
each of the five study groups. The average baseline 
blood pressures and resting heart-rates for the study 
cohort were well within the normal ranges of 121/74 
mm Hg and 70 BPM. At the conclusion of the study 
(75 min.), no increases in either systolic or diastolic 
blood pressures or heart rate were observed. None of 
the  baseline-ending  changes  approached  statistical 
significance nor were there any statistically significant 
differences between any of the five study groups. 
Table 3 depicts the results of the self-report rat-
ings for the 10 symptoms. As compared to the placebo 
group, none of the changes in these 10 self-reported 
symptoms were statistically significant either 45 or 75 
min. from baseline. No significant effects relative to 
the placebo group were observed by the participants 
in the four treatment groups for symptoms including 
anxiety,  hunger,  tension,  sleepiness,  energy,  nerv-
ousness,  headache,  upset  stomach,  concentration  or 
general discomfort. 
 
Table 2. Blood Pressures and Resting heart Rates 
Treatment  
Variable 
Placebo  T2  T3  T4  T5  P-Value1 
SYSTOLIC             
 Baseline   122.9(17.7)    120.5(14.5)    120.0(12.3)    117.9(14.4)    125.6(12.6)   0.794 
 Ending  123.3(18.3)  120.3(9.0)  120.9(11.4)  119.3(15.5)  130.8(10.2)   0.317 
DIASTOLIC             
 Baseline    71.3(6.9)    73.8(6.4)    77.0(6.3)    72.7(9.8)   76.9(6.4)   0.316 
 Ending    75.0(9.1)   74.6(8.3)    75.5(10.0)    71.8(10.0)   75.3(7.8)   0.891 
HEART RATE             
 Baseline    64.5(11.2)     72.3(5.1)   70.0(14.0)    71.6(13.3)    69.4(6.4)    0.518 




 1ANOVA. Placebo: V-8 juice only, T2: 50 mg of p-synephrine (Advantra Z®). T3: p-synephrine + 600 mg naringin. T4: p-synephrine + 600 mg 
naringin + 100 mg hesperidin. T5: p-synephrine + 600 mg naringin + 1,000 mg hesperidin. Each value is the mean with the standard devia-
tion for 10 subjects. 
 
Table 3. Mean changes from baseline in each rating for placebo and each treatment group with p values for between groups 










Using  a  double-blinded,  randomized,  place-
bo-controlled  protocol,  this  study  compared  the  ef-
fects of 50 mg p-synephrine (as Advantra Z®) alone 
with three different amounts of hesperidin and nar-
ingin on: (1) resting metabolism rate, (2) blood pres-
sure,  (3)  resting  heart-rate,  and  (4)  self-reported 
mood/energy  levels  in  healthy  human  subjects.  As 
expected,  the  RMR  of  the  placebo  group  decreased 
over the 75 min. test-retest period since subjects con-
tinued the 8-10 hour fast they began prior to the start 
of the study (Figure 1). The addition of p-synephrine, 
hesperidin, and naringin led to increases in RMR over 
placebo. However, while adding 100 mg of hesperidin 
in Group 4 led to an increase in RMR over placebo, an 
unexpected  reduction  was  observed  in  the  RMR  in 
Group 5 which received 1000 mg hesperidin as com-
pared to Group 4. These data indicate that increasing 
the  hesperidin  from  100  mg  to  1,000  mg  reversed 
some of the thermogenic effects of 100 mg hesperidin 
in combination with 50 mg p-synephrine plus 600 mg 
naringin. It may be that in this case, more is not better, 
and increasing the amount of hesperidin constitutes 
an example of hormesis [30, 31].  
The  increase  in  the  metabolic  rate  between 
p-synephrine alone and the placebo control was ap-
proximately 6.9 %. This increase in thermogenesis is 
similar to the increases reported in previous studies 
involving p-synephrine [17, 18]. The increase in RMR 
between  Group  4,  the  combination  of  p-synephrine 
with 600 mg naringin and 100 mg hesperidin, and the 
placebo  control  is  approximately  17.7  %.  If  one  as-
sumes that the product was taken twice a day for one 
year, the theoretical increase in calorie consumption 
would amount to over 31 pounds. However, the ac-
tual  extent  of  weight  loss  if  the  product  was  con-
sumed  under  these  conditions  remains  to  be  deter-
mined. 
The mechanism by which naringin and hesperi-
din  increase  the  thermogenic  effect  of  p-synephrine 
may involve enhancing the expression of adiponectin 
which is known to play a role in lipid and glucose 
metabolism.  Liu  et  al.  [32]  have  shown  that 
naringenin  and  hesperetin  up-regulate  adiponectin 
expression, and both activate the peroxisome prolif-
erator-activated receptor-γ (PPARγ) which has been 
recognized as the master regulator of adipocyte dif-
ferentiation.  In  addition,  naringenin  also  possessed 
significant  ability  to  activate  PPARα  [32],  a  major 
regulator of lipid metabolism in the liver.  
Products  with  thermogenic  properties  are  fre-
quently associated with elevated blood pressures and 
heart-rates.  p-Synephrine  is  a  phenylethylamine  de-
rivative  with  some  structural  similarities  to  ephed-
rine, and is thus assumed to exert cardiovascular ef-
fects by many authors [see for example, 20, 21, 33-35]. 
However, no effects on heart rate or blood pressure 
were  observed  in  response  to  p-synephrine  or 
p-synephrine in combination with naringin and hes-
peridin (Table 2). p-Synephrine differs from ephedrine 
in that it has a hydroxyl group on the para position of 
the benzene ring and lacks the methyl group on the 
side  chain  of  the  molecule.  These  structural  differ-
ences greatly alter the pharmacokinetic and receptor 
binding properties of p-synephrine, resulting in little 
or no cardiovascular effects [27], as confirmed by this 
study.  No  adverse  events  have  been  directly  at-
tributable  to  bitter  orange  extract  and  p-synephrine 
[36,  37].  However,  caffeine  is  commonly  present  in 
products  that  contain  p-synephrine  [19,  28],  and  is 
well  known  to  produce  cardiovascular  effects  [38], 
particularly in caffeine-sensitive individuals [39].  
The absence of changes in blood pressure, rest-
ing heart-rate and self-ratings in the four treatment 
groups  involving  p-synephrine,  naringin  and  hes-
peridin relative to the placebo group is very positive, 
and in conjunction with the increased thermogenesis 
may result in the development of beneficial products 
with respect to weight loss and weight management. 
The  findings  were  further  substantiated  by  con-
sistency of the results across all four treatment groups. 
However, longer term studies are required to assess 
the amount of weight that is actually lost in response 
to  these  products,  and  to  provide  information  con-
cerning safety when used over an extended period of 
time. 
A problem faced in studies of thermogenic ef-
fects  is  that  noticeable  changes  in  the  mood  states 
listed in Table 1 often make subjects aware of whether 
or not they are receiving a placebo, thus undermining 
blinding of the study. The lack of significant differ-
ences between the treatment groups and the control 
group with respect to the self-report ratings of symp-
toms increases confidence in the safety of the combi-
nation as well as in the blinding procedure used in 
this study.  
Strengths of the study are the use of randomized 
placebo-controlled double-blinded study design, the 
absence of thermogenic changes in the placebo group, 
the  absence  of  adverse  effects  on  blood  pressure, 
heart-rate  and  self-reports  in  the  four  treatment 
groups, the consistency of the effects of p-synephrine 
on  metabolism  in  all  treatment  groups,  and  the  in-
creases in RMR in the treatment groups. The weak-
ness of this study is the small number (10) of subjects 
in the placebo and in each of the treatment groups. 




spect to hesperidin where an increased amount may 
lead to a masking of the thermogenic effects found 
with lesser amounts.  
Conclusions 
This randomized double-blinded placebo control 
pilot study supports the safety and thermogenic ef-
fects  of  p-synephrine,  particularly  when  combined 
with 600 mg of naringin and 100 mg of hesperidin. No 
increase in heart rate or blood pressure was observed 
over the 75 min. of the study nor were there any dif-
ferences  in  a  self-reported  rating  of  10  common 
symptoms between the treated and placebo groups. 
The data suggests the combination of the flavonoids 
naringin and hesperidin with p-synephrine may assist 
weight management. Further studies are required to 
determine optimal doses as well as safety and efficacy 
associated with long term use. 
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